MX2023004763A - Uso de anticuerpo anti-promiostatina/miostatina latente para tratar la atrofia muscular espinal. - Google Patents

Uso de anticuerpo anti-promiostatina/miostatina latente para tratar la atrofia muscular espinal.

Info

Publication number
MX2023004763A
MX2023004763A MX2023004763A MX2023004763A MX2023004763A MX 2023004763 A MX2023004763 A MX 2023004763A MX 2023004763 A MX2023004763 A MX 2023004763A MX 2023004763 A MX2023004763 A MX 2023004763A MX 2023004763 A MX2023004763 A MX 2023004763A
Authority
MX
Mexico
Prior art keywords
pro
muscular atrophy
spinal muscular
myostatin antibody
latent myostatin
Prior art date
Application number
MX2023004763A
Other languages
English (en)
Inventor
Yung Chyung
Ryan Iarrobino
George Nomikos
Guochen Song
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Publication of MX2023004763A publication Critical patent/MX2023004763A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

La presente divulgación se refiere a métodos terapéuticos, usos y composiciones que comprenden un anticuerpo anti-promiostatina/mios tatina latente para tratar la atrofia muscular espinal (AME) en sujetos humanos, ya sea como monoterapia o como un complemento a terapias dirigidas a la motoneurona, tales como terapias correctoras/reguladoras por incremento de SMN.
MX2023004763A 2020-10-26 2021-10-25 Uso de anticuerpo anti-promiostatina/miostatina latente para tratar la atrofia muscular espinal. MX2023004763A (es)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US202063105850P 2020-10-26 2020-10-26
US202063106172P 2020-10-27 2020-10-27
US202163200955P 2021-04-05 2021-04-05
US202163201157P 2021-04-15 2021-04-15
US202163202317P 2021-06-06 2021-06-06
US202163202372P 2021-06-08 2021-06-08
US202163202900P 2021-06-29 2021-06-29
US202163260725P 2021-08-30 2021-08-30
US202163261398P 2021-09-20 2021-09-20
PCT/US2021/056517 WO2022093724A1 (en) 2020-10-26 2021-10-25 Use of anti-pro/latent myostatin antibody for treating spinal muscular atrophy

Publications (1)

Publication Number Publication Date
MX2023004763A true MX2023004763A (es) 2023-05-09

Family

ID=78622120

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004763A MX2023004763A (es) 2020-10-26 2021-10-25 Uso de anticuerpo anti-promiostatina/miostatina latente para tratar la atrofia muscular espinal.

Country Status (11)

Country Link
US (1) US20240002490A1 (es)
EP (1) EP4232151A1 (es)
JP (1) JP2023549455A (es)
KR (1) KR20230095998A (es)
CN (1) CN116390756A (es)
AU (1) AU2021369471A1 (es)
CA (1) CA3193909A1 (es)
IL (1) IL302132A (es)
MX (1) MX2023004763A (es)
TW (1) TW202233234A (es)
WO (1) WO2022093724A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023215384A2 (en) 2022-05-04 2023-11-09 Scholar Rock, Inc. Use of myostatin inhibitor for treating spinal muscular atrophy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040044063A1 (en) 2002-05-31 2004-03-04 Brent Stockwell SMA therapy and cell based assay for identifying therapies
WO2008127722A1 (en) 2007-04-12 2008-10-23 Paratek Pharmaceuticals, Inc. Methods for treating spinal muscular atrophy using tetracycline compounds
EP3922645A1 (en) 2015-09-15 2021-12-15 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
KR20230169484A (ko) 2016-06-13 2023-12-15 스칼러 락, 인크. 미오스타틴 억제제의 용도 및 조합 요법

Also Published As

Publication number Publication date
WO2022093724A1 (en) 2022-05-05
IL302132A (en) 2023-06-01
AU2021369471A1 (en) 2023-06-15
AU2021369471A9 (en) 2024-02-08
US20240002490A1 (en) 2024-01-04
CA3193909A1 (en) 2022-05-05
KR20230095998A (ko) 2023-06-29
JP2023549455A (ja) 2023-11-27
TW202233234A (zh) 2022-09-01
EP4232151A1 (en) 2023-08-30
CN116390756A (zh) 2023-07-04

Similar Documents

Publication Publication Date Title
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2020010603A (es) Extracto de cáñamo para tratamiento de dolor en animales.
EP4140487A8 (en) Combination therapy for treating cancer
BRPI0810118A8 (pt) Método para tratar doença, método para efetuar profilaxia contra caa, uso de um agente, método para reduzir amilóide vascular em um paciente, e, kit para tratamento
UA94899C2 (ru) Фиксированное дозирование антител к her
MX2020007040A (es) Composiciones que comprenden microbiota coseleccionada y metodos para su uso.
BR112016008010A2 (pt) uso de moléculas de ligação de semaforina-4d para tratamento de aterosclerose
MX2020012018A (es) Composiciones para el tratamiento de condiciones de la piel.
BR112018070017A2 (pt) métodos de tratamento de cânceres pediátricos
EA201590709A1 (ru) Комбинированная терапия и ее применение для лечения димиелинизирующих расстройств
AU2010266004A8 (en) Method of treating cancer with Dll4 antagonist and chemotherapeutic agent
BR112018074619A2 (pt) uso de um anticorpo anti-pd-1 em combinação com um anticorpo anti-cd30 em tratamento com câncer
MX2022000027A (es) Extracto de ca?amo para tratamiento del dolor, cancer y epilepsia en animales.
WO2019067405A3 (en) FORMULATION OF FENFLURAMINE COMPATIBLE WITH A CÉTOGENEOUS REGIMEN
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
MX2023004763A (es) Uso de anticuerpo anti-promiostatina/miostatina latente para tratar la atrofia muscular espinal.
MX2021012035A (es) Metodos para agotar agentes que provocan enfermedades a traves de fagocitosis dirigida de anticuerpos.
MX2020013120A (es) Tratamiento terapéutico de cánceres de microsatélites inestables.
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
MX2021010665A (es) Metodos de tratamiento de amiloidosis al.
BR112019011350A2 (pt) terapia de combinação
CR20210514A (es) USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183)
EA202090741A1 (ru) Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака
TW200833710A (en) Treatment for spinal muscular atrophy
MX2021008716A (es) Metodo para tratar dolor de osteoartritis al administrar resiniferatoxina.